Pfizer Secures Control of Metsera in $9 Billion Deal Amid Bidding War with Novo Nordisk
Metsera
Obesity Drug Developer
Pfizer
Pharmaceutical R&D Developer
The latest information shows,Pfizer Wins Bidding War Against Rival Novo Nordisk for Obesity Biotech Company Metsera
RelevantBackground can be found in the previous text.Latest Development in the Metsera Acquisition Battle: Novo Nordisk Temporarily Takes the Lead
The final price per share in cash reached by the two companies$65.60(approximately$6.9 billion), plus$20.65Or Valuable Rights (CVR), total per share$86.25(Total price approximately$90 billion）。
Metsera's board further determined that, compared to Pfizer's merger proposal, Novo Nordisk's proposed deal would expose the company and its shareholders to unacceptable legal and regulatory risks, including the risk that the initial dividend may not be paid or could subsequently be clawed back.
Metsera's board unanimously reaffirmed its recommendation, urging the company's common shareholders to vote in favor of the amended Pfizer merger agreement at the special meeting, stating that "the board has determined that the revised terms represent the best option for maximizing shareholder value, both in terms of value and transaction certainty."
The two parties expect to quickly complete the transaction after the special shareholders' meeting on November 13.
Previous Review
Review of Innovative Drugs at the Midpoint: A New Starting Point After the Bubble Burst
October: Overview of Financing and Investment in 17 Domestic Biopharmaceutical Enterprises
